The EPS projection of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for period quarter closed 2016-12-31 is $-0.72.
The EPS estimates given 30-days and 1 week ago were $-0.72 and $-0.72, correspondingly. This number 90 and 60 days before was $-0.72 and $-0.72 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 2 mean estimate is $-0.72 based on 4 EPS estimations. As on 2016-08-09 estimated EPS was $-0.91 showing surprise of $-0.17, or -22.97%. Following the given predictions, the standard deviation is $0.23.
The upgrade count for EPS revisions was 0 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 1 and 1 correspondingly, though for a quarter and 120-days ago, it was 1 and 1 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 0 and 1 in that order. But, a quarter and 120-days ago, this numeral was 3 and 3 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 3 and 1, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is $7.89 and the median is $7.52. The estimate is stated by 3 analysts for the fiscal 2016.
The highest yearly projection is $9.45 and lowest sales mark is $6.7. This results a standard deviation of $1.411.
Almost 3 have reviewed sales target for better in the past week and 3 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is 8.23%.
Nearly 3 revised sales predictions for better over the past month and 3 have downgraded forecasts. It suggests an average deviation of 9.965% across given estimates.
Just about 3 have revised sales forecast up over the quarter and 3 have downgraded forecasts, hinting to a deviation of 9.965%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...